AI is starting to reshape how big pharma searches for the next blockbuster drug, and that shift is pulling fresh attention to a handful of companies that talk openly about using algorithms, machine learning and computational chemistry in their pipelines. If you care about where capital may cluster next, ignoring this theme risks missing a potential re-rating story. This article unpacks three AI-exposed giants from the screener and explains why this news flow matters to their stocks.
The three stocks highlighted below are just a sample, and the full screen surfaced 10 more AI-exposed pharma giants with equally compelling stories that are not covered here. To identify, compare, and analyze which ones best fit your own AI-Enabled Big Pharma thesis, head straight into the AI-Enabled Big Pharma screener.
Novartis is one of the purest fits for the AI‑Enabled Big Pharma theme, with a global prescription drugs franchise and AI‑supported R&D helping it sift through complex biology at scale. The analyst consensus Narrative on Simply Wall St highlights how that mix is already feeding into the profit story.
Structural margin work, reflected in a Q3 2026 core operating margin of 41.6% and 40.1% year to date while SG&A declined 7% against 4% sales growth, alongside a reiterated target of at least a 40% margin by 2029 driven largely by SG&A and AI enabled efficiency, points to continued potential for strong core margins and cash generation that can support earnings per share and capital returns.
The real swing factor is how durable those efficiency gains prove if a single key pressure on the cost base shifts direction.
If that pressure point is on your mind, read the full narrative for Novartis to see how AI efficiency, capital returns and potential margin resilience all connect.
Sanofi fits the AI Enabled Big Pharma theme through its use of AI partners in drug discovery while still being, at its core, a large Paris based medicines and vaccines group. The analyst consensus Narrative on Simply Wall St frames how that mix feeds into its long term story.
Sanofi's extended alliance with Regeneron to co develop four long acting IL 4 and IL 13 pathway antibodies and an option on lunsekimig, backed by a €25b 2030 ambition for Dupixent, points to a follow on Type 2 immunology portfolio that could support future revenue and earnings as the current flagship drug matures.
What really matters now is how one less visible pressure on R&D discipline and capital allocation plays out over the next few years.
Sanofi is a €100.4b pharma group that uses AI enabled collaborations to support a broad medicines and vaccines portfolio, generating about €50.4b from Biopharma and €575m from Other operations.
That capital discipline question is exactly what the full narrative for Sanofi unpacks, showing where Sanofi's AI partnerships could be accelerating or masking the next phase of returns.
Adaptive Biotechnologies plugs straight into the AI Enabled Big Pharma theme because its immune medicine platform already blends sequencing data, computational biology and machine learning. The analyst consensus Narrative on Simply Wall St points to one engine in particular that shows how this can translate into real world usage.
Accelerating integration of clonoSEQ into electronic medical records across both academic and community settings, highlighted by strong uptake of serial ordering features in Flatiron’s OncoEMR where over 70% of clinicians choose repeat-interval buttons and roughly three quarters of those orders convert, supports recurring test usage and points to higher clinical volume and revenue over time.
What happens to the whole Adaptive Biotechnologies story if a single less visible lever on that repeat testing habit shifts direction?
Adaptive Biotechnologies is a US$4.6b immune medicine platform business that uses proprietary chemistry, computational biology and machine learning to decode the immune system, generating about US$268 million from MRD testing and US$30 million from Immune Medicine programs.
If that lever is what you are trying to size, the full narrative for Adaptive Biotechnologies shows how Adaptive Biotechnologies' AI engine could decouple test adoption from single channel risk.
Fresh ideas move first. By the time a breakthrough theme hits headlines, early entries often have already caught the breakout momentum. Scan these under the radar lists while it matters and get in early.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com